Andere Sprachen FSD Pharma Inc.

Aktien

A3E2LR

CA35954B4047

HUGE

Verzögert Canadian Securities Exchange Andere Börsenplätze 21:59:04 30.04.2024			% 5 Tage	% 1. Jan.
0.57 ^CAD	-.--%		-10.94%	-52.50%

25.04.	FSD Pharma gibt bekannt, dass Celly Nutrition für die Markteinführung des Nahrungsergänzungsmittels in den USA mit Six+One zusammenarbeitet	MT
08.04.	FSD Pharma erhält Nasdaq-Non-Compliance-Mitteilung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

FSD Pharma Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd in an Induced State of Alcohol Intoxication	13:29
FSD Pharma : Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy ofunbuzzd™ in an Induced State of Alcohol Intoxication - Form 6-K	30.04.
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	30.04.
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd	26.04.
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	25.04.
FSD Pharma Provides another Update on Celly Nu's Anticipated Launch of unbuzzd	23.04.
FSD Pharma : Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products - Form 6-K	17.04.
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption	16.04.
FSD Pharma Receives Nasdaq Non-Compliance Notice	08.04.
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	08.04.
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
FSD Pharma Signs the Agreement With iNGENu CRO to Conduct a Clinical Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adults	28.03.
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO	27.03.
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	27.03.
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd	11.03.
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	11.03.
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 at Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	06.03.
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum	05.03.
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	05.03.
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen FSD Pharma Inc.

Aktien

A3E2LR

CA35954B4047

HUGE

Andere Sprachen

Filter